Two drug development experts join the Baruch S. Blumberg Institute faculty November 11, 2024 Read More »
PROTAC modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro March 1, 2024 Read More »
Blumberg Professor Nicholas Meanwell chosen for top award by the International Society for Antiviral Research September 19, 2023 Read More »
Drug development journal publishes special issue to honor Nicholas Meanwell, Distinguished Professor at the Baruch S. Blumberg Institute August 1, 2023 Read More »
Blumberg Institute awarded federal research contract worth up to $32 million to develop treatment for yellow fever January 17, 2023 Read More »
